人工智能内镜分析在溃疡性结肠炎3期试验中与症状及生活质量的一致性优于传统内镜评分
本研究基于TrueNorth 3期试验的溃疡性结肠炎内镜视频,比较人工智能内镜累积疾病评分(CDS)与Mayo内镜评分(MES)在症状缓解及健康相关生活质量上的一致性。结果显示,CDS与部分Mayo缓解及EuroQol 5 Dimension的一致性均优于MES,且AI评分可能重新定义黏膜愈合。
要点
- 在MES 2、3的内镜活动患者中,达到部分Mayo症状缓解者CDS更低(83.8 vs 186.9,P<0.0001)。
- CDS与EuroQol 5 Dimension的一致性优于MES(κ=0.53 vs 0.44)。
- CDS<40与部分Mayo缓解的一致性优于低MES(κ=0.72 vs 0.57,AUC 0.85)。
核心结论
- AI内镜累积疾病评分(CDS)与症状缓解及健康相关生活质量的一致性优于Mayo内镜评分(MES),可能定量重新定义充分黏膜愈合。
研究设计与样本
- 基于TrueNorth 52周3期试验(比较ozanimod与安慰剂治疗溃疡性结肠炎)的内镜视频,纳入387例受试者。
- 比较维持期结束时CDS与内镜不活动(MES 0、1)vs活动(MES 2、3)组在部分Mayo缓解(PMS≤2)及治疗方面的一致性。
主要发现
- 在内镜活动(MES 2、3)受试者中,达到PMS症状缓解者CDS更低(83.8 vs 186.9,P<0.0001)。
- EuroQol 5 Dimension与CDS的一致性优于MES(κ=0.53 vs 0.44),且CDS能在MES 2、3受试者中检测患者报告健康维度的生活质量差异。
- 与低内镜最大强度(MES 0、1)相比,低累积疾病负担(CDS<40,AUC 0.85)与PMS缓解的一致性更好(κ=0.72 vs 0.57)。
- 当充分内镜标准定义为PMS缓解加低MES或低CDS时,ozanimod与安慰剂的缓解差异从22.6%增至28.6%。
关键数值与推荐
- 低CDS截断值通过Youden指数确定,用于评估与PMS缓解的一致性(Cohen's κ)。
- CDS<40的AUC为0.85;CDS与PMS缓解的κ=0.72,低MES与PMS缓解的κ=0.57。
- CDS与EuroQol 5 Dimension的κ=0.53,MES与EuroQol 5 Dimension的κ=0.44。
临床怎么用
- AI内镜CDS可辅助评估溃疡性结肠炎黏膜愈合,与症状及生活质量一致性更好。
- 在MES 2、3患者中,CDS有助于识别症状缓解亚组。
- 将CDS纳入充分内镜标准可能提高临床试验中治疗组间缓解差异的检出。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Ulcerative colitis (UC) disease assessment considers both mucosal healing and symptoms which can disagree. We compared the artificial intelligence (AI) endoscopic cumulative disease score (CDS) with the Mayo endoscopic score (MES) for agreement with symptoms and health related quality of life (HR-QoL) in UC. METHODS: Endoscopic video was obtained from TrueNorth, a 52-week phase 3 trial comparing ozanimod (OZA) with placebo (PBO) for UC. End of maintenance CDS was compared with endoscopically inactive (MES 0, 1) vs active (MES 2, 3) groups by partial Mayo remission (PMS, ≤2) and treatment using the Mann-Whitney U test. CDS and MES were compared with EuroQol 5 Dimension HR-QoL measures using the Kruskal-Wallis test. Low CDS cutoff for PMS remission used the Youden index, with agreement to PMS assessed using Cohen's κ. RESULTS: In 387 subjects, among endoscopically active subjects (MES 2, 3), the CDS was lower in those achieving PMS symptomatic remission (83.8 vs 186.9, P < 0.0001). EuroQol 5 Dimension had better agreement with CDS than MES (κ = 0.53 vs 0.44) and detected QoL differences within MES 2, 3 subjects for patient-reported health dimensions. Compared with low endoscopic maximum intensity (MES 0, 1), low-cumulative disease burden (CDS <40, area under the curve 0.85) had better agreement with PMS remission (κ = 0.57 vs 0.72). When defining adequate endoscopic criteria as PMS remission plus either low MES or low CDS, the difference between OZA vs PBO remission increased from 22.6% to 28.6%. DISCUSSION: AI-enabled endoscopic scoring has better agreement with symptomatic remission and HR-QoLs compared with MES and could quantitatively redefine adequate mucosal healing.
引用
- Stidham RW, Cai L, Wittrup E, et al. Artificial Intelligence Analysis of Endoscopy Outperforms Conventional Endoscopic Scoring for Agreement With Symptoms and Quality of Life in a Phase 3 Ulcerative Colitis Trial. Am J Gastroenterol. 2025. PMID: 41247057. doi:10.14309/ajg.0000000000003838
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。